203 related articles for article (PubMed ID: 37770706)
1. Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States.
Mody RR; Meyer KL; Ward JM; O'Day KB
Diabetes Ther; 2023 Dec; 14(12):2045-2055. PubMed ID: 37770706
[TBL] [Abstract][Full Text] [Related]
2. Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates.
Reitzel SB; Bøgelund M; Basse A; Barszczewska O; Ren H
Curr Med Res Opin; 2023 Aug; 39(8):1055-1060. PubMed ID: 37415503
[TBL] [Abstract][Full Text] [Related]
3. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
[TBL] [Abstract][Full Text] [Related]
4. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
Urva S; Levine JA; Schneck K; Tang CC
Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
[TBL] [Abstract][Full Text] [Related]
5. Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States.
Zhang X; McAdam Marx C
J Manag Care Spec Pharm; 2023 Mar; 29(3):276-284. PubMed ID: 36840958
[No Abstract] [Full Text] [Related]
6. Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Hunt B; Hansen BB; Ericsson Å; Kallenbach K; Ali SN; Dang-Tan T; Malkin SJP; Valentine WJ
Adv Ther; 2019 Dec; 36(12):3483-3493. PubMed ID: 31650514
[TBL] [Abstract][Full Text] [Related]
7. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Johansen P; Sandberg A; Capehorn M
Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
[TBL] [Abstract][Full Text] [Related]
8. Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.
Valentine WJ; Hoog M; Mody R; Belger M; Pollock R
Diabetes Obes Metab; 2023 May; 25(5):1292-1300. PubMed ID: 36655340
[TBL] [Abstract][Full Text] [Related]
9. Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.
Viljoen A; Pantalone KM; Galindo RJ; Cui X; Huh R; Hemmingway A; Fernández Landó L; Patel H
Diabetes Ther; 2023 May; 14(5):925-936. PubMed ID: 37000390
[TBL] [Abstract][Full Text] [Related]
10. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
11. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.
Wilkinson L; Hunt B; Johansen P; Iyer NN; Dang-Tan T; Pollock RF
Diabetes Ther; 2018 Jun; 9(3):951-961. PubMed ID: 29557057
[TBL] [Abstract][Full Text] [Related]
12. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
Johansen P; Hunt B; Iyer NN; Dang-Tan T; Pollock RF
Adv Ther; 2019 May; 36(5):1190-1199. PubMed ID: 30875029
[TBL] [Abstract][Full Text] [Related]
13. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
Azuri J; Hammerman A; Aboalhasan E; Sluckis B; Arbel R
Diabetes Obes Metab; 2023 Apr; 25(4):961-964. PubMed ID: 36507900
[TBL] [Abstract][Full Text] [Related]
14. Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
Boye KS; Sapin H; Dong W; Williamson S; Lee CJ; Thieu VT
Diabetes Ther; 2023 Nov; 14(11):1867-1887. PubMed ID: 37668888
[TBL] [Abstract][Full Text] [Related]
15. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
[TBL] [Abstract][Full Text] [Related]
16. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA; D'Alessio DA
Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
[TBL] [Abstract][Full Text] [Related]
17. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K
Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829
[TBL] [Abstract][Full Text] [Related]
18. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States.
Mody R; Valentine WJ; Hoog M; Sharland H; Belger M
J Manag Care Spec Pharm; 2024 Feb; 30(2):153-162. PubMed ID: 38308628
[TBL] [Abstract][Full Text] [Related]
19. The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain.
Vidal J; Malkin SJP; Hunt B; Martín V; Hallén N; Javier Ortega F
Diabetes Ther; 2020 Feb; 11(2):509-521. PubMed ID: 31925724
[TBL] [Abstract][Full Text] [Related]
20. Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis.
Igarashi A; Hunt B; Wilkinson L; Langer J; Pollock RF
Adv Ther; 2020 Oct; 37(10):4446-4457. PubMed ID: 32870471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
